CRP and diabetes mellitus: In March and April 2020, in New York City, 14.2% of 2634 patients were treated in intensive care units, 12.2% received invasive mechanical ventilation, and 21% died.[6] Obesity, hypertension, diabetes, and other comorbidities were associated with severe or fatal outcomes.[7] Several laboratory biomarkers, including lymphopenia and the levels of C-reactive protein (CRP), procalcitonin (PCT), and lactate dehydrogenase (LDH), have been used to stratify disease severity.[8,9] An early biomarker of severity would identify patients requiring hospitalization or intensive care.